Biarnes Carrera Marc, Sevko Alexandra, Glanville Nicholas, Deban Livija
Prokarium London UK.
Eng Biol. 2024 May 31;8(2-3):31-40. doi: 10.1049/enb2.12032. eCollection 2024 Jun-Sep.
Living cures are cell-based, programmable therapies that integrate the latest learnings in immunology and synthetic biology. Although Adoptive Cell Therapies (ACTs) have transformed the treatment landscape of haematological malignancies by harnessing the powerful anti-tumour properties of immune cells, commercialisation and ensuring access is challenging. Their application in solid tumour treatment has been hindered by the immunosuppressive tumour microenvironment (TME) and its associated physical barriers. Conversely, bacterial immunotherapies offer cost-effective solutions by utilising tumour-colonising bacteria that trigger localised inflammatory responses within the TME. The authors briefly examine advancements in ACT and propose bacterial immunotherapies as an alternative or complementary treatment modality with potential use either as standalone therapies or in conjunction with other treatments.
活体疗法是基于细胞的可编程疗法，融合了免疫学和合成生物学的最新研究成果。尽管过继性细胞疗法（ACTs）通过利用免疫细胞强大的抗肿瘤特性改变了血液系统恶性肿瘤的治疗格局，但商业化及确保其可及性仍具有挑战性。它们在实体瘤治疗中的应用受到免疫抑制性肿瘤微环境（TME）及其相关物理屏障的阻碍。相反，细菌免疫疗法通过利用定殖于肿瘤的细菌在TME内引发局部炎症反应，提供了具有成本效益的解决方案。作者简要探讨了ACT的进展，并提出细菌免疫疗法作为一种替代或补充治疗方式，具有作为单一疗法或与其他治疗联合使用的潜在用途。
